Oxford spinout Alethio raises $90M Series A for chronic blood cancer trials, co-led by Sofinnova Partners and RA Capital.
PRIVATENov 05, 2026
Amount Raised
$90 Million
Round Type
Series A
OxfordBiotechnologyHealth CareMedicalTherapeutics
Investors
University Of OxfordCancer Research HorizonsOxford Science EnterprisesRA CapitalSofinnova Partners
Description
Alethio, a biotech spinout from Oxford's MRC Weatherall Institute, raised $90M in Series A funding to advance clinical trials for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. The round was co-led by Sofinnova Partners and RA Capital, with participation from founding investor Oxford Science Enterprises, Cancer Research Horizons, and the University of Oxford. Founded in late 2021, Alethio was created by merging two Oxford research groups studying malignant stem cells and platelet-producing cells. The company is developing a therapeutic approach targeting G6B, a protein selectively expressed on disease-driving cells, to treat MPNs including essential thrombocythemia.
Who to call at Alethio, and when
A new round usually means Alethio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Alethio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Alethio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alethio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Alethio
Location
Oxford, England, United Kingdom
About
Alethio is an Oxford spinout founded in 2021 that develops targeted therapies for chronic blood cancers, specifically myeloproliferative neoplasms (MPNs). The company uses its proprietary ARTEMIS platform to identify and validate drug targets on cancer-sustaining cells by combining single-cell analysis, computational methods, and laboratory testing. Alethio's lead program, ATX-011, is a G6B-targeting antibody designed to selectively eliminate disease-driving stem cells while sparing healthy ones. The company aims to offer more selective treatment approaches for blood cancers like essential thrombocythemia and myelofibrosis.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alethio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
OxfordBiotechnologyHealth CareMedicalTherapeutics